

萩原淳司 :

1. Kawamura E, Shiomi S, Kotani K, Kawabe J, Hagihara A, Fujii H, Uchida-Kobayashi S, Iwai S, Morikawa H, Enomoto M, Murakami Y, Tamori A, Kawada N.

Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma.

J Gastroenterol Hepatol. 2014 Sep;29(9):1722-7.

2. Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T.

A phase I study of the combination chemotherapy of sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.

Cancer Sci. 2014 Mar;105(3):354-8

3. Motoyama H, Komiya T, Thuy le TT, Tamori A, Enomoto M, Morikawa H, Iwai S, Uchida-Kobayashi S, Fujii H, Hagihara A, Kawamura E, Murakami Y, Yoshizato K, Kawada N.

Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver.

Lab Invest. 2014 Feb;94(2):192-207.

4. Hai H, Tamori A, Enomoto M, Morikawa H, Uchida-Kobayashi S, Fujii H, Hagihara A, Kawamura E, Thuy le TT, Tanaka Y, Kawada N.

Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.

J Gastroenterol Hepatol. 2014 Jan;29(1):201-7.

5. Hagihara A, Teranishi Y, Kawamura E, Fujii H, Iwai S, Morikawa H, Enomoto M, Tamori A, Kawada N.

A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.

Intern Med. 2013;52(14):1589-92.

6. Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono K, Seki S, Fukushima S, Tsao MS, Sugimura T, Ushijima T.

Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers.

Oncogene. 2004 Nov 11;23(53):8705-10.

山下聡 :

1. Takahashi T, Yamashita S, Matsuda Y, Kishino T, Nakajima T, Kushima R, Kato K, Igaki H, Tachimori Y, Osugi H, Nagino M and Ushijima T. ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. J Cancer Res Clin Oncol, 141:453-463 (2015).

2. Yamaguchi T, Mukai H, Yamashita S, Fujii S and Ushijima T. Comprehensive DNA methylation and extensive mutation analyses of HER2-positive breast cancer. Oncology, online.

3. Zong L, Hattori N, Yoda Y, Yamashita S, Takeshima H, Takahashi T, Maeda M, Katai

H, Nanjo S, Ando T, Seto Y, and Ushijima T. Establishment of a DNA Methylation Marker to Evaluate Cancer Cell Fraction in Gastric Cancer. Gastric Cancer, in press.

4. Takeshima H, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis. 2014 Dec 4. pii: bgu238. [Epub ahead of print]

金井雅史 :

1. Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T.

Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Pancreas. 2014 Apr;43(3):411-6.

2. Kanai M.

Therapeutic application of curcumin for patients with pancreatic cancer World Journal of Gastroenterology 2014 in press

3. Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, Kawaguchi Y, Takaori K, Matsumoto S, Uemoto S, Chiba T.

Neutrophil-to-Lymphocyte Ratio for Predicting Palliative Chemotherapy Outcomes in Advanced Pancreatic Cancer Patients Cancer Medicine 2014 Feb 12. Doi: 1002/cam4.204

河田則文 :

1. Fujii H, Kawada N.

Fibrogenesis in alcoholic liver disease. World J Gastroenterol. 2014 Jul 7;20(25):8048-54.

2. Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, Iwasa M, Tokumoto Y, Endo R, Kawamura NH, Shiraki M, Habu D, Tsuruta S, Miwa Y, Kawaguchi A, Kakuma T, Sakai H, Kawada N, Hanai T, Takahashi S, Kato A, Onji M, Takei Y, Kohgo Y, Seki T, Tamano M, Katayama K, Mine T, Sata M, Moriwaki H, Suzuki K.

Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2014 Jun;12(6):1012-8.

村上善基 :

1. Murakami Y, Tanahashi T, Okada R, Toyoda H, Kumada T, Enomoto M, Tamori A, Kawada N, Taguchi YH, Azuma T.

Comparison of hepatocellular carcinoma miRNA expression profiling as evaluated by next generation sequencing and microarray. PLoS One. 2014 Sep 12;9(9):e106314.

2. Taguchi YH, Murakami Y.

Universal disease biomarker: can a fixed set of blood microRNAs diagnose multiple diseases? BMC Res Notes. 2014 Aug 30;7:581.

田守昭博 :

1. Hai H, Tamori A, Kawada N.

Role of hepatitis B virus DNA integration in human hepatocarcinogenesis.
World J Gastroenterol. 2014 May 28;20(20):6236-43.

2. Tamori A, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, Enomoto M, Murakami Y, Kawada N.
Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy.
J Gastroenterol Hepatol. 2014 Sep;29(9):1715-21.

平川弘聖 :

1. Kimura K, Amano R, Nakata B, Yamazoe S, Hirata K, Murata A, Miura K, Nishio K, Hirakawa T, Ohira M, Hirakawa K.
Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
World J Surg Oncol. 2014 Nov 27;12:360.

2. Hirata K, Nakata B, Amano R, Yamazoe S, Kimura K, Hirakawa K.
Predictive factors for change of diabetes mellitus status after pancreatectomy in preoperative diabetic and nondiabetic patients.
J Gastrointest Surg. 2014 Sep;18(9):1597-603.